arrow
C

Charlab, Rosane

us food & drug administration (fda)
H指数:0
被引数:83

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum

FDA批准摘要: Alpelisib用于PIK3CA-Related过度生长谱

2023-08-257
OA
FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements
2023-06-087
OA
FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

FDA批准摘要: Amivantamab用于治疗EGFR外显子20插入突变的非小细胞肺癌患者

2023-04-0626
PRE
FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement
2022-10-0722
OA
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors
2022-06-2163
OA
FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation
2022-03-0831
OA
FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer
2021-12-1629
OA
FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions
2021-05-2721
OA
FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions
2020-11-2598
OAAI
FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer
2020-11-0989
PREAI
FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation

FDA批准摘要: Ivosidenib用于异柠檬酸脱氢酶-1突变的复发或难治性急性髓系白血病

2019-06-03113
OAAI
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy
2018-09-0494
OAAI
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer
2017-11-30138
PREAI
FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs
2016-09-1559
OAAI